WO2021056815A1 - 一种化疗免疫组合药物及其制备方法 - Google Patents
一种化疗免疫组合药物及其制备方法 Download PDFInfo
- Publication number
- WO2021056815A1 WO2021056815A1 PCT/CN2019/122492 CN2019122492W WO2021056815A1 WO 2021056815 A1 WO2021056815 A1 WO 2021056815A1 CN 2019122492 W CN2019122492 W CN 2019122492W WO 2021056815 A1 WO2021056815 A1 WO 2021056815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- imiquimod
- immune
- sodium alginate
- chemotherapeutic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 293
- 230000000973 chemotherapeutic effect Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title abstract description 69
- 229940079593 drug Drugs 0.000 title abstract description 67
- 238000002360 preparation method Methods 0.000 title description 30
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 238
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 238
- 239000000661 sodium alginate Substances 0.000 claims abstract description 238
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 238
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 143
- 229960002751 imiquimod Drugs 0.000 claims abstract description 123
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical group C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims abstract description 123
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 91
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 91
- 239000002671 adjuvant Substances 0.000 claims abstract description 54
- 238000003756 stirring Methods 0.000 claims abstract description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229940044519 poloxamer 188 Drugs 0.000 claims abstract description 37
- 229920001993 poloxamer 188 Polymers 0.000 claims abstract description 37
- 230000002163 immunogen Effects 0.000 claims abstract description 36
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 31
- 239000000839 emulsion Substances 0.000 claims abstract description 28
- 230000001954 sterilising effect Effects 0.000 claims abstract description 22
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 21
- 239000012528 membrane Substances 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims description 149
- 238000011282 treatment Methods 0.000 claims description 71
- 239000008176 lyophilized powder Substances 0.000 claims description 63
- 238000002512 chemotherapy Methods 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 49
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 46
- 229940000425 combination drug Drugs 0.000 claims description 40
- -1 polyethylene Polymers 0.000 claims description 31
- 239000004094 surface-active agent Substances 0.000 claims description 28
- 235000010443 alginic acid Nutrition 0.000 claims description 23
- 229920000615 alginic acid Polymers 0.000 claims description 23
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 20
- 229940072056 alginate Drugs 0.000 claims description 20
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 20
- 229920000053 polysorbate 80 Polymers 0.000 claims description 20
- 206010009944 Colon cancer Diseases 0.000 claims description 17
- 208000029742 colonic neoplasm Diseases 0.000 claims description 17
- 238000004108 freeze drying Methods 0.000 claims description 16
- UOHPEWIBMAQKCN-UHFFFAOYSA-N 1,3,5,5,6-pentafluoro-1,3-diazinane-2,4-dione Chemical compound FC1C(C(N(C(N1F)=O)F)=O)(F)F UOHPEWIBMAQKCN-UHFFFAOYSA-N 0.000 claims description 12
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 claims description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001304 Solutol HS 15 Polymers 0.000 claims description 10
- 239000004359 castor oil Substances 0.000 claims description 10
- 235000019438 castor oil Nutrition 0.000 claims description 10
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 10
- 229940068968 polysorbate 80 Drugs 0.000 claims description 10
- 229940114069 12-hydroxystearate Drugs 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 239000004698 Polyethylene Substances 0.000 claims description 9
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 9
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 9
- 229940044476 poloxamer 407 Drugs 0.000 claims description 9
- 229920001992 poloxamer 407 Polymers 0.000 claims description 9
- 229920000573 polyethylene Polymers 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 8
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 claims description 8
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 8
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229960005277 gemcitabine Drugs 0.000 claims description 8
- 239000003053 toxin Substances 0.000 claims description 8
- 231100000765 toxin Toxicity 0.000 claims description 8
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 7
- 229960001467 bortezomib Drugs 0.000 claims description 7
- 239000000568 immunological adjuvant Substances 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical group OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 229940124669 imidazoquinoline Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 49
- 238000011065 in-situ storage Methods 0.000 abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 22
- 201000011510 cancer Diseases 0.000 abstract description 16
- 206010027476 Metastases Diseases 0.000 abstract description 12
- 230000009401 metastasis Effects 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 7
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 5
- 238000000498 ball milling Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007761 synergistic anti-cancer Effects 0.000 abstract description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 180
- 239000007924 injection Substances 0.000 description 180
- 239000000243 solution Substances 0.000 description 131
- RGKLRAHQVIHCCH-UHFFFAOYSA-N 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine;hydrochloride Chemical compound Cl.C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 RGKLRAHQVIHCCH-UHFFFAOYSA-N 0.000 description 94
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 76
- 241000699670 Mus sp. Species 0.000 description 59
- 239000000499 gel Substances 0.000 description 59
- 239000007864 aqueous solution Substances 0.000 description 49
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 48
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 24
- 230000002601 intratumoral effect Effects 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 22
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 20
- 229920001222 biopolymer Polymers 0.000 description 20
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 20
- 239000008055 phosphate buffer solution Substances 0.000 description 20
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 229910001424 calcium ion Inorganic materials 0.000 description 19
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 18
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000013268 sustained release Methods 0.000 description 16
- 239000012730 sustained-release form Substances 0.000 description 16
- 230000004614 tumor growth Effects 0.000 description 16
- 239000011259 mixed solution Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 235000010407 ammonium alginate Nutrition 0.000 description 13
- 239000000728 ammonium alginate Substances 0.000 description 13
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 13
- 235000010408 potassium alginate Nutrition 0.000 description 13
- 239000000737 potassium alginate Substances 0.000 description 13
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 13
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 12
- 238000002648 combination therapy Methods 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 12
- 229940009456 adriamycin Drugs 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002271 resection Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 238000007674 radiofrequency ablation Methods 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- UWNXGZKSIKQKAH-SSEXGKCCSA-N (2R)-2-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methylamino]-3-hydroxypropanoic acid Chemical compound Cc1cc(CN[C@H](CO)C(O)=O)c(OCc2cccc(c2)C#N)cc1OCc1cccc(c1C)-c1ccc2OCCOc2c1 UWNXGZKSIKQKAH-SSEXGKCCSA-N 0.000 description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 description 6
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 4
- 241001474374 Blennius Species 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 4
- 229930126263 Maytansine Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229960001904 epirubicin Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 4
- 229960001156 mitoxantrone Drugs 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZEZZLZKHZPMELC-SDQLLZIZSA-N (3R)-4-[[(2R)-1-[[(2R)-5-amino-1-[[(2R)-1-[[(2R)-1-[[(1R)-1-carboxy-2-phenylethyl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-[[(2R,3S)-2-[[(2R)-1-[(2R)-6-amino-2-[[(2R)-2-[[(2R)-2-[[(2R)-2,4-diamino-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoic acid Chemical compound C[C@H](O)[C@@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CCCCN)NC(=O)[C@@H](CO)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@H](N)CC(N)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](Cc1c[nH]cn1)C(=O)N[C@H](Cc1ccccc1)C(O)=O ZEZZLZKHZPMELC-SDQLLZIZSA-N 0.000 description 3
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 3
- MXKLDYKORJEOPR-UHFFFAOYSA-N 3-(5-fluoro-1h-indol-3-yl)pyrrolidine-2,5-dione Chemical compound C12=CC(F)=CC=C2NC=C1C1CC(=O)NC1=O MXKLDYKORJEOPR-UHFFFAOYSA-N 0.000 description 3
- JEDPSOYOYVELLZ-UHFFFAOYSA-N COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O Chemical compound COc1nc(OCc2cccc(c2C)-c2ccccc2)ccc1CNCCNC(C)=O JEDPSOYOYVELLZ-UHFFFAOYSA-N 0.000 description 3
- QRXBPPWUGITQLE-UHFFFAOYSA-N Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 Chemical compound Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1 QRXBPPWUGITQLE-UHFFFAOYSA-N 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 3
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 3
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 229950006370 epacadostat Drugs 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- KRTIYQIPSAGSBP-KLAILNCOSA-N linrodostat Chemical compound C1(CCC(CC1)C1=C2C=C(F)C=CC2=NC=C1)[C@@H](C)C(=O)NC1=CC=C(Cl)C=C1 KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 229940085675 polyethylene glycol 800 Drugs 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229950010550 resiquimod Drugs 0.000 description 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003381 solubilizing effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000037967 hot tumor Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000004082 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000037966 cold tumor Diseases 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 229940068998 egg yolk phospholipid Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011297 radiofrequency ablation treatment Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of drugs for the treatment of tumors, in particular to a drug composition for chemotherapy and immunity combined therapy, as well as a preparation method and application.
- Chemotherapy is currently one of the three main treatment methods for clinical treatment of tumors. Most cancer patients need to receive a certain degree of chemotherapy. For those tumors that are prone to metastasis or have metastasized, chemotherapy is the main treatment method. However, traditional chemotherapeutics also damage normal organs, and the commonly used clinical chemotherapy modes are systemic administration, which is not very selective for the lesions, and the side effects of chemotherapy are very large.
- the immune checkpoint blockade represents the encouraging achievements of tumor immunotherapy in recent years, this therapy still has important limitations, including low clinical response rate (about 20%) and non-specific immune response. Side effects etc.
- the current low clinical response rate of clinical immune checkpoint blocking therapy means that most patients do not respond to this expensive therapy.
- the technical problem to be solved by the present invention is to provide a new type of chemotherapeutic immune drug composition, which can produce a synergistic anti-cancer effect, and reduce side effects, reduce the probability of cancer metastasis, and reduce the probability of cancer recurrence. It can effectively kill tumors in situ while inhibiting the immune response, reducing the growth of distant metastatic tumors and the probability of tumor recurrence. At the same time, the production process is optimized and the product stability is good.
- the present invention provides the following technical solutions:
- a chemotherapeutic and immune combination drug which contains a chemotherapeutic drug that can cause immunogenic death and an immune adjuvant, characterized in that: the chemotherapy and immune combination drug comprises a first mixture and a second mixture, and the first mixture contains an immune adjuvant
- the second mixture contains a chemotherapeutic agent that can cause immunogenic death; the chemotherapeutic agent that can cause immunogenic death is oxaliplatin, and the immunological adjuvant is imiquimod R837, which also includes Poloxamer 188 and sodium alginate ALG;
- the first mixture is that the imiquimod R837 and poloxamer 188 are mixed and ball milled to obtain a uniformly dispersed imiquimod emulsion, and the imiquimod particles have a particle size of 0.5-3 microns.
- the special emulsion is sterilized by high temperature, humidity and heat;
- the second mixture is that the sodium alginate ALG and oxaliplatin are stirred and mixed with water, and filtered through a micron filter membrane to sterilize the mixture to prepare a mixture;
- the first mixture and the second mixture are mixed to form a chemotherapy and immune combination drug.
- a chemotherapeutic immune combination drug which contains a chemotherapeutic drug that can cause immunogenic death and an immune adjuvant:
- the chemotherapy and immune combination drug includes a first mixture and a second mixture, the first mixture contains an immune adjuvant, and the The second mixture contains a chemotherapeutic agent that can cause immunogenic death;
- the chemotherapeutic agent that can cause immunogenic death is oxaliplatin, the immunological adjuvant is imiquimod R837, and also includes poloxamer 188 and sodium alginate ALG;
- the first mixture is that the imiquimod R837 and poloxamer 188 are mixed and ball milled to obtain a uniformly dispersed imiquimod emulsion.
- the imiquimod particles have a particle size of 0.5-3 microns.
- Mott emulsion, oxaliplatin and water are mixed and stirred evenly and sterilized by high temperature and humidity;
- the second mixture is that the sodium alginate is mixed with water, and then filtered and sterilized by a micron filter membrane to prepare a mixture;
- the first mixture and the second mixture are mixed to form a chemotherapy and immune combination drug.
- the mass ratio of imiquimod R837 and poloxamer 188 is 1: (0.1-5), and the high temperature sterilization is 105° C. to 150 °C humid heat sterilization for 10-15 minutes;
- the second mixture is filtered and sterilized through a 0.22 micron filter membrane, and lyophilized to form a lyophilized powder.
- the mass ratio of imiquimod R837 and poloxamer 188 is 1: (0.1-5), and the high temperature sterilization is 105° C. to 150 °C humid heat sterilization for 10-15 minutes;
- the second mixture is filtered and sterilized through a 0.22 micron filter membrane, and lyophilized to form a lyophilized powder.
- a chemotherapeutic immune combination drug which contains a chemotherapeutic drug capable of causing immunogenic death and an immune adjuvant
- the chemotherapy and immune combination drug comprises a first mixture and a second mixture, the first mixture contains the immune adjuvant, the The second mixture contains chemotherapeutics that can cause immunogenic death;
- the first mixture is that the immune adjuvant is imiquimod, imiquimod and surfactant are mixed and ball milled to obtain a uniformly dispersed imiquimod emulsion, and the imiquimod particles are 0.5-300 microns Particle size, imiquimod emulsion is sterilized by high temperature, humid heat, and the surfactant is poloxamer 407, or polysorbate 80 (Tween 80), or polyethylene glycol-12-hydroxystearate (Solutol HS 15), or egg yolk lecithin, or polyoxyethylene (35) castor oil, or vitamin E succinate polyethylene glycol ester, or one or more of sodium hydroxymethyl cellulose;
- the second mixture is a mixture of sodium alginate and oxaliplatin, which is stirred and mixed with water, and filtered through a micron filter membrane to sterilize the mixture;
- the first mixture and the second mixture are mixed to form a chemotherapy and immune combination drug.
- the sodium alginate is replaced with chitosan, or fibrinogen, or alginate, or hyaluronic acid;
- the imiquimod R837 is replaced with imidazoquinoline, or glucopyranoside lipid
- oxaliplatin Oxa is replaced with anthracyclines, or cyclophosphamide, or bortezomib, or gemcitabine, or pentafluorouracil, or toxin.
- a chemotherapeutic and immune combination drug which contains a chemotherapeutic drug that can cause immunogenic death and an immune adjuvant, characterized in that: the chemotherapy and immune combination drug comprises a first mixture and a second mixture, and the first mixture contains an immune adjuvant The second mixture contains a chemotherapeutic drug that can cause immunogenic death;
- the first mixture is that the imiquimod R837 and the surfactant are mixed and ball milled to obtain a uniformly dispersed imiquimod emulsion.
- the imiquimod particles have a particle size of 0.5-3 microns.
- the emulsion is mixed with oxaliplatin and water and stirred evenly and then sterilized by high temperature and humidity;
- the surfactant is poloxamer 407, or polysorbate 80 (Tween 80), or polyethylene glycol-12-hydroxystearate (Solutol HS 15), or egg yolk lecithin, or polyoxyethylene One or more of ethylene (35) castor oil, or vitamin E succinate polyethylene glycol ester, or sodium hydroxymethyl cellulose;
- the second mixture is that the sodium alginate is mixed with water, and then filtered and sterilized by a micron filter membrane to prepare a mixture;
- the first mixture and the second mixture are mixed to form a chemotherapy and immune combination drug.
- the sodium alginate can be replaced with chitosan, or fibrinogen, or alginate, or hyaluronic acid;
- the imiquimod R837 can be replaced with imidazoquinoline, or glucopyranoside lipid;
- the oxaliplatin Oxa can be replaced with anthracyclines, or cyclophosphamide, or bortezomib, or gemcitabine, or pentafluorouracil, or toxin.
- a method for preparing a chemotherapy and immune combination drug which is characterized in that it comprises the following steps:
- the first step Weigh imiquimod R837 and surfactant poloxamer 188 according to the ratio 1: (0.1-5), add water ball mill for 2-3 hours, take out the homogenate after completion, add water, stir and mix, 105 °C ⁇ 150°C damp heat sterilization for 10-15 minutes;
- Step 2 Weigh sodium alginate ALG and oxaliplatin, add water, stir, filter and sterilize the obtained solution through a micron filter membrane; after pre-cooling, perform freeze-drying;
- the third step Add the second lyophilized powder of the mixture to the first solution of the mixture, shake and mix well, and then inject.
- a chemotherapeutic and immune combination drug for the treatment of colon cancer tumors which contains a chemotherapeutic drug and an immune adjuvant that can cause immunogenic death, and is characterized in that: the chemotherapy and immune combination drug comprises a first mixture and a second mixture.
- One mixture contains an immunological adjuvant, and the second mixture contains a chemotherapeutic drug that can cause immunogenic death;
- the first mixture is that the immune adjuvant is imiquimod, imiquimod and surfactant are mixed and ball milled to obtain a uniformly dispersed imiquimod emulsion, and the imiquimod particles are 0.5-3 microns Particle size, imiquimod emulsion is sterilized by high temperature, humid heat, and the surfactant is poloxamer 407, or polysorbate 80 (Tween 80), or polyethylene glycol-12-hydroxystearate (Solutol HS 15), or egg yolk lecithin, or polyoxyethylene (35) castor oil, or vitamin E succinate polyethylene glycol ester, or one or more of sodium hydroxymethyl cellulose;
- the second mixture is a mixture of sodium alginate and oxaliplatin, which is stirred and mixed with water, and filtered through a micron filter membrane to sterilize the mixture;
- the first mixture and the second mixture are mixed to form a chemotherapy and immune combination drug.
- the present invention also provides an in-situ gel-forming chemotherapeutic immunotherapy biopolymer pharmaceutical composition, which contains: the first component is alginate, which can form a porous gel with calcium ions in the body,
- the alginate is one or more of sodium alginate, potassium alginate and ammonium alginate;
- the second component is chemotherapeutics that can cause immunogenic death
- the third group of components are immune adjuvants.
- the immune adjuvant is imiquimod (R837), CpG oligonucleotide, monophosphoryl lipid A and requine One or more of mods.
- the second type of chemotherapeutics that can cause immunogenic death are anthracyclines such as adriamycin and epirubicin
- anthracyclines such as adriamycin and epirubicin
- vitamins, mitoxantrone, oxaliplatin, cyclophosphamide, bortezomib, gemcitabine, pentafluorouracil, and toxins such as maytansine.
- in-situ gel-forming chemotherapy and immune combined therapy biopolymer pharmaceutical composition it also includes a fourth type of component immune checkpoint inhibitor or IDO inhibitor, the fourth type of component immune checkpoint inhibitor
- Antibodies usually include anti-CTLA-4, anti-PD-1 and anti-PD-L1
- small molecule inhibitors usually include CA-170, PM-327, BMS-8, BMS-37, BMS-202, BMS -230, BMS242, BMS-1001, BMS-1166, BMS-1001, BMS-1166 and JQ1, peptide inhibitors include DPPA-1;
- the IDO inhibitors include small molecules such as BMS-986205, IDO inhibitor 1, NLG919, NLG8189, PF-06840003, Epacadostat and 4-phenylimidazole.
- the first type of component is sodium alginate
- the second type of component is doxorubicin hydrochloride
- the third The class component is imiquimod
- the mass ratio of sodium alginate, adriamycin hydrochloride and imiquimod is 50-800 to 1-100 to 1-100.
- the mass ratio of sodium alginate, adriamycin hydrochloride and imiquimod is 200-400 to 10 to 75 to 10 to 75.
- the sodium alginate concentration is more than 5 mg/ml.
- a method for preparing a biopolymer pharmaceutical composition for in-situ gel-forming chemotherapy and immunotherapy comprising:
- the first type of component is sodium alginate
- the second type of component is oxaliplatin
- the third The class component is imiquimod hydrochloride
- the mass ratio of sodium alginate, oxaliplatin and imiquimod is 50-800 to 1-75 to 1-100.
- the mass ratio of sodium alginate, oxaliplatin and imiquimod is 200-400 to 10 to 75 to 10 to 75.
- the method for preparing the in-situ gel-forming chemotherapeutic immune combined therapy biopolymer pharmaceutical composition includes:
- the first type component is sodium alginate
- the second type component is pentafluorouracil
- the third type group Divided into imiquimod hydrochloride
- the first type component is sodium alginate
- the second type component is cyclophosphamide
- the third type component is imiquimod hydrochloride.
- the first type of component is sodium alginate; the second type of component is doxorubicin hydrochloride or oxaliplatin; and third The first component is imiquimod hydrochloride; the fourth component is anti-PDL1 antibody.
- the first type of component is potassium alginate or ammonium alginate
- the second type of component is doxorubicin hydrochloride or oxaliplatin
- the third component is imiquimod hydrochloride
- the fourth component is anti-PDL1 antibody.
- An in-situ gel-forming chemotherapeutic immune combined therapy biopolymer pharmaceutical composition consisting of: the first component is alginate, said alginate can form a porous gel with calcium ions in the body, said seaweed
- the acid salt is one or more of sodium alginate, potassium alginate and ammonium alginate;
- the second type of component is a chemotherapeutic agent that can cause immunogenic death;
- the third type of component is an immune adjuvant.
- An in-situ gel-forming chemotherapeutic immune combined therapy biopolymer pharmaceutical composition consisting of: the first component is alginate, said alginate can form a porous gel with calcium ions in the body, said seaweed
- the acid salt is one or more of sodium alginate, potassium alginate and ammonium alginate;
- the second type of chemotherapeutics that can cause immunogenic death are anthracyclines such as adriamycin and epirubicin , Mitoxantrone, oxaliplatin, cyclophosphamide, bortezomib, gemcitabine, pentafluorouracil and one or more of toxins such as maytansine;
- the third component is an immune adjuvant, the immune The adjuvant is one or more of imiquimod (R837), CpG oligonucleotide, monophosphoryl lipid A and resiquimod.
- An in-situ gel-forming chemotherapeutic immune combined therapy biopolymer pharmaceutical composition consisting of: the first component is alginate, said alginate can form a porous gel with calcium ions in the body, said seaweed
- the acid salt is one or more of sodium alginate, potassium alginate and ammonium alginate;
- the second type of chemotherapeutics that can cause immunogenic death are anthracyclines such as adriamycin and epirubicin , Mitoxantrone, oxaliplatin, cyclophosphamide, bortezomib, gemcitabine, pentafluorouracil and one or more of toxins such as maytansine;
- the third component is an immune adjuvant, the immune The adjuvant is one or more of imiquimod (R837), CpG oligonucleotide, monophosphoryl lipid A and resiquimod;
- the fourth type of component immune checkpoint inhibitors or IDO inhibitors the fourth type of component immune checkpoint inhibitor antibodies usually have anti-CTLA-4, anti-PD-1 and anti-PD-L1, small molecules Inhibitors usually include CA-170, PM-327, BMS-8, BMS-37, BMS-202, BMS-230, BMS242, BMS-1001, BMS-1166, BMS-1001, BMS-1166 and JQ1, peptides Class inhibitors include DPPA-1;
- the IDO inhibitors include BMS-986205, IDO inhibitor 1, NLG919, NLG8189, PF-06840003, Epacadostat and 4-phenylimidazole small molecules.
- An in-situ gel-forming, chemotherapy and immune combined therapy biopolymer pharmaceutical composition consisting of: the first type of component is sodium alginate, the second type of component is doxorubicin hydrochloride; the third type of component is imiquimol Particularly, the mass ratio of the sodium alginate, adriamycin hydrochloride and imiquimod is 50-800 to 1-100 to 1-100.
- the present invention provides a series of pharmaceutical compositions.
- this composition system there are mainly four types of components.
- the first type of components can be combined with other types of components according to the actual situation, including:
- the first type of component sodium alginate excipients, which can produce gel with calcium ion plasma in the human body or animal body;
- the second component chemotherapeutics that cause immunogenic death
- the third component immune adjuvant
- the fourth component immune checkpoint inhibitors or IDO inhibitors.
- the first type of component excipients, usually sodium alginate, potassium alginate, ammonium alginate, etc. These polysaccharides will cross-link each other to form gels when they encounter divalent ions such as calcium ions, so when the drug is wrapped in it Later, the formed gel can effectively slow the release of the drugs in it, thereby enhancing the efficacy and reducing the side effects.
- Sodium alginate is a natural polysaccharide, which has the stability, solubility, viscosity and safety required for pharmaceutical excipients.
- Sodium alginate has been widely used in the food industry and medicine.
- Sodium alginate is the most widely used water-soluble alginate.
- Sodium alginate can quickly undergo ion exchange when encountering calcium ions to form a gel, and there are sufficient calcium ions in the human body or animal body, so it can form gel in situ in the body.
- the two alginates, potassium alginate and ammonium alginate although the cations contained in them are different from sodium alginate, they can also be cross-linked with calcium ions to form a porous gel, thereby acting as a slow-release drug.
- sodium alginate is usually extracted from seaweed, so sodium alginate is a better choice.
- the second component chemotherapeutics that can cause immunogenic death
- anthracyclines such as doxorubicin, epirubicin, mitoxantrone, etc.
- oxaliplatin such as doxorubicin
- cyclophosphamide such as cyclophosphamide
- bortezo Rice gemcitabine
- pentafluorouracil and toxins such as maytansine and so on.
- These drugs have been clinically approved, and recent studies have shown that these drugs can cause the immunogenic death of cancer cells.
- These dead cancer cells express calreticulin, which is easily recognized and taken up by immune cells, especially antigen-presenting cells. , To help immune cells recognize tumor cells and cause an effective anti-tumor immune response.
- immune adjuvants are non-specific immune proliferatives, which refer to auxiliary substances that can enhance the body's immune response to antigens or change the type of immune response together with antigens or pre-injected into the body.
- immune adjuvants There are many types of immune adjuvants, and there is no unified classification method.
- Freund's adjuvant and cytokine adjuvant are more commonly used.
- the immunobiological effects of immune adjuvants are to enhance immunogenicity, enhance antibody titer, change the type of antibody production, cause or enhance delayed hypersensitivity reactions, but the specific mechanism of immune adjuvants is not yet fully understood. Different adjuvants The mechanism of action is also different.
- TLR Toll-like receptors
- immunomodulators include immune checkpoint inhibitors or IDO inhibitors.
- Immune checkpoint inhibitors include antibody inhibitors or small molecule inhibitors.
- Antibody inhibitors usually include anti-CTLA-4, anti-PD-1 and anti-PD-L1, and small molecule inhibitors usually include CA-170. , PM-327, BMS-8, BMS-37, BMS-202, BMS-230, BMS242, BMS-1001, BMS-1166, BMS-1001, BMS-1166 and JQ1.
- Peptide inhibitors include DPPA-1.
- IDO inhibitors include small molecules such as BMS-986205, IDO inhibitor 1, NLG919, NLG8189, PF-06840003, Epacadostat and 4-phenylimidazole, which can inhibit IDO enzymes and enhance the effect of antigen presenting cells. Because tumor cells deceive the immune system and escape the immune response, these antibodies are needed to suppress the immune response that protects the tumor, so that immune cells can better kill tumor cells.
- the first type of component excipients can also be referred to as component one; the second type of component ICD chemotherapeutic drugs can also be referred to as component two; the third type of component immune adjuvant can also be referred to as component three; the fourth type of component immune Checkpoint inhibitors can also be referred to as component four.
- Freeze-dried powder is a sterile powder injection prepared by freezing the medicinal solution into a solid in a sterile environment, and vacuuming the water to sublimate and dry it.
- the preparation process of the mixed medicinal solution of component one, component two, component three and component four and freeze-dried preparation is as follows.
- This patent mainly relates to four types of raw material ingredients: the first type of component excipient sodium alginate (solid powder), the second type of component ICD type chemotherapeutics (solid powder), the third type of component immune adjuvant (solid powder) , The fourth component of immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 or anti-PD-L1 antibodies, commercial products for clinical use, with freeze-dried powder or injection as raw materials).
- Preparation scheme 1 Mix the solid powders of component one excipient, component two ICD chemotherapeutics, and component three immune adjuvant in a certain proportion and put them into a large beaker, add deionized water (or physiological saline, or phosphate buffer solution) ), at room temperature 25 degrees Celsius, stir with a stirring blade at a speed of 50 to 500 revolutions per minute until the solution is clear and transparent; if necessary, formulate component four immune checkpoint inhibitors into injections according to the product instructions, and add them to the above mixed solution; After the above solution is evenly stirred, take out a separate bottle and freeze-dry it. After the lyophilized powder is reconstituted, there should be no turbidity and flocculent precipitation.
- Preparation scheme 2 Weigh component 1, component 2, and component 3 of the target mass, respectively, add deionized water (or physiological saline, or phosphate buffer solution) to prepare three separate solutions; Prepare the injection solution in four parts according to the product instructions; mix the above-mentioned solutions in a suitable volume ratio, stir with a stirring blade at a rotation speed of 50 to 500 revolutions per minute at 25 degrees Celsius at room temperature until the solution is uniform and not turbid, take out the divided bottle and freeze-dry. After the lyophilized powder is reconstituted, there should be no turbidity and flocculent precipitation. There is little difference between Option 1 and Option 2.
- deionized water or physiological saline, or phosphate buffer solution
- Preparation scheme 3 Weigh component 1, component 2, and component 3 of the target mass, respectively, add deionized water (or physiological saline, or phosphate buffer solution) to prepare three independent solutions; According to the product instructions, it is divided into four to prepare injections; for ICD drugs containing hydrochloride, the solutions of component 2, component 3, and component 4 need to be stirred and mixed first, and during the stirring process (25 degrees Celsius, the stirring paddle is used Rotation speed 50 to 300 revolutions per minute) slowly drop the solution of component 1 until the whole solution is evenly stirred.
- deionized water or physiological saline, or phosphate buffer solution
- Usage plan 1 After re-dissolving the lyophilized powder injection of the composition of the above four types of components in physiological saline, the composition solution is directly injected into the tumor site of the patient through clinical interventional administration and direct puncture administration. The multi-point injection method is adopted to ensure that the composition solution evenly fills the entire tumor. After the composition is injected into the tumor, firstly, the first type of component alginate will form a gel when it encounters calcium ions. The first type of component will quickly gel after encountering calcium ions in the tissue.
- a porous network cross-linked structure is formed, so that the other three types of components mixed in the alginate can be slowly released, thereby enhancing its effect and reducing toxic and side effects;
- the second type of component ICD chemotherapeutics can not only kill effectively Tumor cells can also cause immunogenic death, produce tumor-related antigens, and activate tumor-specific immune responses; again, the third type of immune adjuvant enhances the ability of antigen-presenting cells to further amplify the corresponding immune response;
- the use of the fourth component of immune checkpoint inhibitors or IDO inhibitors prevents the metastatic tumor from escaping the immune response, so that immunotherapy can kill the tumor more effectively, thereby inhibiting tumor metastasis and recurrence.
- usage plan 2 After re-dissolving the lyophilized powder injection of the composition of the first, second, and third components in physiological saline, the composition solution is directly injected into the patient through clinical interventional administration and direct puncture administration At the tumor site, multi-point injection is used during injection to ensure that the composition solution evenly fills the entire tumor.
- This treatment method is recommended to be used in combination with the fourth component of immune checkpoint inhibitors: the combination plan includes the addition of immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 Or anti-PD-L1 antibody) or IDO inhibitor, one-time intratumor local injection; it can also be an intravenous injection of immune checkpoint inhibitor after local treatment of a mixture of one, two, and three components. (Reference example in embodiment twelve)
- Use plan three the composition of four components is sprayed on the wound, and then the calcium ion solution is sprayed to form a gel
- the tumor patient has a normal surgical resection of the lesion, considering the problem that the surgical resection cannot completely remove the tumor cells in the lesion, it can be
- the freeze-dried powder injections of the above four types of components are reconstituted with physiological saline, and then sprayed on the wound site after surgical resection with a syringe or spray bottle, and then an appropriate amount of calcium chloride solution can be sprayed on the site to make it gel.
- the wound is sutured. This program helps to eliminate the remaining cancer cells, and can inhibit tumor metastasis and recurrence. (Example Sixteen)
- Usage plan four (the composition of three components is sprayed on the wound, and then the calcium ion solution is sprayed to form a gel + the fourth component is combined for use): after the normal surgical resection of the lesion site, the surgical resection is considered incomplete
- the freeze-dried powder injections of the first, second, and third components can be reconstituted with normal saline, and then sprayed on the wound site after surgical resection with a syringe or spray bottle. Spray an appropriate amount of calcium chloride solution on the site to make it gel, and finally suture the wound. This program helps to eliminate the remaining cancer cells, and can inhibit tumor metastasis and recurrence.
- the combination plan includes the addition of immune checkpoint inhibitors (anti-CTLA- 4. Anti-PD-1 or anti-PD-L1 antibody) or IDO inhibitor, one-time intratumor local injection; it can also be intravenously administered after local treatment of a mixture of one, two, and three components Inject immune checkpoint inhibitors.
- Alginate is a natural polysaccharide, which is safe and non-toxic, has good biocompatibility, and can be degraded. It is a good biological material.
- the commonly used method is to combine alginate and calcium ions in vitro to form a gel implantable material. This method of use not only limits its application in the body, it often requires surgery or intervention, which is difficult to operate. The damage to the patient is large, and it is not conducive to combined drug treatment. Therefore, we inject alginate into the tumor, use the calcium ions in the tumor tissue to make the sodium alginate gel in situ in the tumor, and use the formed cross-linked structure to slowly release the drug mixed in the alginate , The sustained-release effect is better.
- This technology has broad application prospects. It can be directly injected with a syringe for the treatment of tumors, with simple operation and low invasiveness. It can also be sprayed on the wound site after the operation with a sprayer, and combined with the operation to clean the residual cancer cells, it is expected to be targeted at different Patients are given personalized treatment, and the cost is low.
- the third type of immune adjuvant mentioned in the technical scheme has not been clinically used to directly treat tumors.
- These small molecule immunomodulators themselves do not have antiviral and antitumor effects, and are often used as auxiliary adjuvants of vaccines to enhance the immunogenicity of antigens.
- Imiquimod R873
- the technology of this patent uses ICD chemotherapeutics and immune adjuvants to be injected together.
- ICD drugs kill tumors to produce tumor antigens, antigens and adjuvants act like tumor vaccines, which can not only inhibit metastasis, but also prevent tumors. relapse.
- the technology of this patent creates a new strategy for the direct treatment of tumors with immune adjuvants and chemotherapeutic drugs.
- the pharmaceutical composition formed by mixing the relevant components of this patent can produce a distinctive and unexpected synergistic anti-cancer effect, and can reduce the side effects of conventional treatments, reduce the probability of cancer metastasis, and reduce the probability of cancer recurrence, providing a Efficient tumor-specific immunotherapy can effectively kill tumors in situ while suppressing the immune response, reducing the growth of distant metastatic tumors and the probability of tumor recurrence, which can help patients under the premise of relatively controlling costs Extend the life cycle and improve the quality of life.
- the related technical solutions in this patent can solve the problem of imiquimod insoluble in water, the problem of stability of imiquimod after sterilization, and the problem of sterilization of sodium alginate.
- sodium alginate and imiquimod R837 cannot be mixed together.
- Sodium alginate ALG needs to be filtered and sterilized, but R837 particles cannot be filtered (the minimum particle diameter after ball milling is 500nm, and filter sterilization requires 220nm filter membrane, so it cannot pass); on the other hand, R837 needs to be sterilized by moist heat, and sodium alginate ALG will degrade at high temperature. Both R837 and ALG cannot be sterilized together.
- Sodium alginate is a relatively special natural biopolymer material.
- Poloxamer 188 is particularly preferred. Without the addition of poloxamer 188, after the R837 ball mill emulsion is sterilized by moist heat at 121°C, it will cause the emulsion to become unstable and produce obvious precipitation and particles, and the water dispersibility is greatly reduced. Poloxamer 188 can greatly help R837 Ensure water dispersibility and stability after sterilization.
- the combined use of sodium alginate, chemotherapeutics, and immune adjuvants can achieve a relatively excellent therapeutic effect.
- sodium alginate, chemotherapeutics and immune adjuvants, and then Adding poloxamer 188 to form a composition can produce better therapeutic effects without the need to combine PD-1, and the effect is better, but the treatment cost is lower. See Figure 30 and Figure 31 for specific experimental data. .
- Fig. 1 is the preparation process of the lyophilized powder injection of the composition of sodium alginate and imiquimod hydrochloride in Example 1, and the instructions for use thereof.
- Fig. 2 is a scanning electron microscope picture of the composition of sodium alginate and imiquimod hydrochloride in Example 1 after the lyophilized powder injection was reconstituted into a gel.
- Figure 3 is the release curve and data statistics of imiquimod drug at different concentrations of sodium alginate in Example 1.
- Fig. 4 is the release curve and data statistics of imiquimod drug at different concentrations of imiquimod in Example 1.
- Figure 5 is a scanning electron microscope picture of the lyophilized powder injection of the composition of sodium alginate and CpG oligonucleotide in Example 2 after being reconstituted into a gel.
- Fig. 6 is the release curve and data statistics of CpG drug at different concentrations of sodium alginate in Example 2.
- Fig. 7 is a CpG drug release curve and data statistics under different CpG concentrations in Example 2.
- Fig. 8 is a scanning electron microscope picture of the composition of sodium alginate and adriamycin hydrochloride in Example 3 after the freeze-dried powder injection was reconstituted into a gel.
- Figure 9 is the release curve and data statistics of doxorubicin hydrochloride drug at different concentrations of sodium alginate in Example 3.
- Fig. 10 is the release curve and data statistics of doxorubicin hydrochloride at different concentrations of doxorubicin hydrochloride in Example 3.
- Fig. 11 is a scanning electron microscope picture of the composition of sodium alginate and oxaliplatin in Example 4 after the freeze-dried powder injection was reconstituted into a gel.
- Figure 12 is the oxaliplatin drug release curve and data statistics at different concentrations of sodium alginate in Example 4.
- Figure 13 is the oxaliplatin drug release curve and data statistics when the concentration of oxaliplatin in Example 4 is different.
- Figure 14 is a scanning electron microscope picture of the sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride freeze-dried powder injection in Example 5 after being reconstituted into a gel.
- Fig. 15 shows the rheological performance test of sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride freeze-dried powder injection after reconstitution in Example 5.
- Figure 16 is a scanning electron microscope picture of the lyophilized powder injection of sodium alginate, oxaliplatin and imiquimod hydrochloride in Example 6 after being reconstituted into a gel.
- Fig. 17 is a scanning electron microscope picture of sodium alginate, adriamycin hydrochloride, imiquimod hydrochloride, and anti-PDL1 antibody freeze-dried powder injection in Example 9 after being reconstituted into a gel.
- Figure 18 shows the detection of antibody activity after reconstitution of sodium alginate, adriamycin hydrochloride, imiquimod hydrochloride and anti-PDL1 antibody freeze-dried powder injection in Example 9.
- Figure 19 shows the tumor growth curve and data statistics of the combination of sodium alginate and imiquimod hydrochloride in Example 13 combined with radiofrequency ablation therapy and anti-PDL1 antibody therapy on a mouse colon cancer tumor model.
- Figure 20 shows the tumor growth curve and data statistics of the combination of sodium alginate and imiquimod hydrochloride in Example 13 in combination with HIFU treatment and anti-PDL1 antibody treatment on a mouse colon cancer tumor model.
- Figure 21 shows the growth curve and data statistics of the second planting tumor caused by the combination of sodium alginate and imiquimod hydrochloride in Example 13 in combination with HIFU treatment and anti-PDL1 antibody treatment on a mouse colon cancer tumor model .
- Figure 22 shows the tumor growth curve and data statistics of the lyophilized powder of the composition of sodium alginate and oxaliplatin in Example 14 after treatment of colon cancer in mice.
- Fig. 23 shows the body weight curve and data statistics of mice treated with colon cancer of the lyophilized powder of the composition of sodium alginate and oxaliplatin in Example 14.
- Figure 24 is an in situ tumor growth curve after treatment with sodium alginate, oxaliplatin, imiquimod hydrochloride and anti-PDL1 antibody in a mouse bilateral tumor model in Example 15.
- Figure 25 shows the growth curve and data statistics of the distal tumor after treatment with sodium alginate, oxaliplatin, imiquimod hydrochloride and anti-PDL1 antibody in a mouse bilateral tumor model in Example 15.
- Fig. 26 shows the tumor growth curve and data statistics of sodium alginate, oxaliplatin, imiquimod hydrochloride and anti-PDL1 antibody in the mouse bilateral tumor model after being cured and re-inoculated with the tumor in Example 15.
- Figure 27 shows the fluorescence imaging data of mice after treatment with sodium alginate, doxorubicin hydrochloride, imiquimod hydrochloride, and anti-PDL1 antibody on a mouse orthotopic breast cancer tumor model in Example 16.
- Figure 28 shows the tumor growth curve and data statistics after treatment with sodium alginate, doxorubicin hydrochloride, imiquimod hydrochloride and anti-PDL1 antibody in the mouse brain cancer model in Example 17.
- Figure 29 shows the fluorescence imaging data of mice after treatment with sodium alginate, doxorubicin hydrochloride, imiquimod hydrochloride and anti-PDL1 antibody on the mouse tumor surgical resection model in Example 18.
- Figure 30 shows the tumor growth of different treatment modalities by direct drug injection to a larger tumor (initial volume> 120 cubic millimeters) in Example 19.
- Figure 31 shows the growth of the contralateral small tumor (initial volume ⁇ 50 mm) in Example 19 without direct injection of drugs and different treatment methods.
- Example 1 Preparation and use of lyophilized powder injection of sodium alginate (first component) and imiquimod (third component) hydrochloride composition
- Step 1 Preparation of Imiquimod (the third component) hydrochloride.
- the purpose of this step is to change the water-insoluble imiquimod into the water-soluble hydrochloride form.
- the lyophilization time is long enough to ensure the complete removal of hydrochloric acid residues.
- Step 2 Preparation of the lyophilized powder injection of the composition of sodium alginate (the first component) and imiquimod (the third component) hydrochloride can adopt the following three methods.
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate and 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and dissolve in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50 ⁇ 300 rpm to After the solution is clear and transparent, the temperature is maintained at 20-40 degrees Celsius and the pH is ⁇ 6.5. The solution is freeze-dried to obtain the composition freeze-dried powder injection.
- Method 2 Weigh 10 to 80 mg of sodium alginate and dissolve in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50 to 300 revolutions per minute until the solution is clear and transparent, freeze-dry to obtain a freeze-dried powder injection, and then mix with 0.1 ⁇ 10 mg of imiquimod hydrochloride freeze-dried powder is uniformly mixed by shaking and mixing the solid to obtain a composition freeze-dried powder injection.
- Method 3 Dissolve 0.1-10 mg of imiquimod hydrochloride lyophilized powder in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then add 10 to sodium alginate. 80 mg is dissolved in the aqueous phase solution, and the continuously stirred imiquimod hydrochloride solution is dripped at a volume ratio of 1 to 20 to ensure that the mixture is clear and transparent without flocculent precipitation. After all the sodium alginate solution has been added, the mixed solution is taken out and freeze-dried to obtain a composition freeze-dried powder injection.
- Figure 1 shows the preparation process of the lyophilized powder injection of the composition of sodium alginate (the first component) and imiquimod (the third component) hydrochloride, and the instructions for use thereof.
- Fig. 2 is a scanning electron microscope picture of a freeze-dried powder injection of a composition prepared by the method described in Fig. 1 after gelling. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Step 3 Release curve of imiquimod in the lyophilized powder injection of the composition of sodium alginate (the first component) and imiquimod (the third component) hydrochloride.
- the drug sustained-release carrier means that the drug slowly enters the blood to reduce the blood drug concentration, and the preparation of sustained-release long-acting drugs that can slowly release the drug components is often very necessary in the treatment.
- the drug release curve refers to the release of the encapsulated drug after we simulate the composition in vitro to form a gel.
- the following is the release curve obtained by fixing the dosage of imiquimod and changing the dosage of sodium alginate.
- Preparation of sodium alginate (first component) and imiquimod (third component) hydrochloride composition freeze-dried powder injection, wherein the sodium alginate concentration is 1, 10, 20, 40 and 80 mg, Imiquimod is 2 mg.
- the lyophilized powder injection of the composition is re-dissolved in 1 ml of aqueous solution and shaken until it is clear and transparent.
- 200 ⁇ l of 5 mg per ml of calcium chloride solution is added to make it into a gel, and chlorine is added.
- the reason for calcification is to simulate the situation that the composition is injected into the tumor in vitro to meet the gelation of calcium ions and then the sustained release of the drug, and the gel is soaked in 1 ml of phosphate buffer solution and stirred. 0.5, 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of imiquimod.
- Figure 3 shows the drug release curve and statistical table of imiquimod at different concentrations of sodium alginate. It can be seen from the figure that when the concentration of sodium alginate is 5 mg/ml and above, imiquimod has an obvious sustained release Therefore, the concentration of sodium alginate in the composition is preferably 5 mg/ml to 80 mg/ml. When the concentration of sodium alginate is 10 mg/ml, it has been optimized. When the concentration of sodium alginate is 20 mg/ml, it basically reaches the peak value. When the concentration is increased again, the effect is not improved significantly.
- the following is the release curve obtained by fixing the dosage of sodium alginate and changing the dosage of imiquimod.
- Preparation of sodium alginate (first component) and imiquimod (third component) hydrochloride composition freeze-dried powder injection, wherein the concentration of imiquimod is 1, 2.5, 5, 7.5 and 10 mg (Maximum solubility).
- Sodium alginate is 20 mg.
- the lyophilized powder injection of the composition is re-dissolved in 1 ml of aqueous solution and shaken until it is clear and transparent, and then 5 mg per ml of calcium chloride solution is added to make it gel, and The colloid was immersed in 1 ml of phosphate buffer solution and stirred, and the drug content in the phosphate buffer solution was determined on the 0th, 0.25, 0.5, 1, 2, 4, and 8 days as the release of imiquimod.
- Figure 4 shows the imiquimod drug release curve and statistical table at different concentrations of imiquimod. It can be seen from the figure that when the concentration of imiquimod is higher than 7.5 mg/ml, the composition has obvious gel formation Rapid drug release, and subsequent release is faster than the low concentration, but the sustained release effect is still obvious, so the concentration of imiquimod in the composition freeze-dried powder injection is selected to be 0.1-10 mg/ml. This shows that imiquimod is effective regardless of the concentration. Although the high concentration will release quickly, it also has an obvious slow-release effect.
- the preferred mass ratio of sodium alginate and imiquimod hydrochloride obtained through the above experiment is 50-800 to 1-100, and the more preferred mass ratio is 200-400 to 10-75.
- Example 2 Lyophilized powder injection of the composition of sodium alginate (the first component) and CpG oligonucleotide (the third component)
- Step 1 Preparation of freeze-dried powder injection of the composition of sodium alginate and CpG oligonucleotide
- Figure 5 is a scanning electron microscope picture of the composition after the freeze-dried powder injection is reconstituted into a gel. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Step 2 CpG release curve in the freeze-dried powder injection of the composition of sodium alginate and CpG oligonucleotide
- the following is the release curve obtained by fixing the dosage of CpG oligonucleotide and changing the dosage of sodium alginate.
- composition freeze-dried powder injection wherein the sodium alginate concentration is 1, 10, 20, and 40 mg, and the CpG oligonucleotide is 0.2 mg, and the composition freeze-dried powder injection is reconstituted separately Dissolve in 1 ml of aqueous solution and shake until it is clear and transparent, then add 200 ⁇ l of 5 mg per ml of calcium chloride solution to make it gel, and soak the gel in 1 ml of phosphate buffer solution and stir. , 0.5, 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of CpG oligonucleotides.
- Figure 6 shows the release curve of CpG drug at different concentrations of sodium alginate. It can be seen from the figure that when the concentration of sodium alginate is 20 mg or more, CpG oligonucleotides have an obvious slow-release phenomenon, so the composition freezes
- the concentration of sodium alginate in the dry powder injection is selected from 5 mg/ml to 80 mg/ml. When the concentration of sodium alginate is 1 mg/ml, the effect is not obvious. When the concentration of sodium alginate is 10 mg/ml, the effect has been optimized. When the concentration of sodium alginate is 20 mg/ml, it basically reaches the peak value, and the concentration is increased. When, the effect is not obvious anymore.
- the following is the release curve obtained by fixing the amount of sodium alginate and changing the amount of CpG oligonucleotide.
- Preparation of sodium alginate and CpG oligonucleotide composition freeze-dried powder injection, wherein the CpG oligonucleotide concentration is 0.1, 0.25, 0.5, 1, and 2 mg, sodium alginate is 20 mg, and the composition is freeze-dried powder injection Re-dissolve in 1 ml of the aqueous solution and shake until it is clear and transparent, then add 5 mg per ml of calcium chloride solution to make it gel, and soak the gel in 1 ml of phosphate buffer solution and stir. 0.5, 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of CpG oligonucleotides.
- Figure 7 shows the release curve of CpG drug at different concentrations of CpG oligonucleotides. From Figure 8 it can be seen that when the concentration of CpG oligonucleotides is higher than 1 mg/ml, there is a relatively obvious acute release, and the subsequent release rate There is not much change. For cost considerations, the price of CpG oligonucleotides is almost RMB 10,000/mg. Therefore, the concentration of CpG oligonucleotides in the composition freeze-dried powder injection is selected to be 0.1-2 mg/ml, preferably The concentration of CpG oligonucleotide is selected to be 0.1-0.5 mg/ml.
- the optimal mass ratio of sodium alginate and CpG oligonucleotide obtained through the above experiment is 50-800 to 1-20, and the more preferable mass ratio is 200-400 to 1-20.
- Example 3 Lyophilized powder injection of the composition of sodium alginate (the first component) and doxorubicin hydrochloride (the second component)
- Step 1 Preparation of freeze-dried powder injection of the composition of sodium alginate and adriamycin hydrochloride:
- Method 1 Weigh 20 ⁇ 80 mg of sodium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride and dissolve in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50 to 300 revolutions per minute until the solution is clear and transparent, and then The solution is freeze-dried to obtain the composition freeze-dried powder injection.
- Method 2 Dissolve 0.1-10 mg of adriamycin hydrochloride in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then dissolve 10 to 80 mg of sodium alginate In the aqueous solution, drip the constantly stirred adriamycin hydrochloride solution at a volume ratio of 1 to 20 to ensure that the mixture is clear and transparent without flocculent precipitation. After all the sodium alginate solution has been added, the mixed solution is taken out and freeze-dried to obtain a composition freeze-dried powder injection.
- Figure 8 is a scanning electron microscope picture of the composition after the freeze-dried powder injection is reconstituted into a gel. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Step 2 Release curve of adriamycin in the freeze-dried powder injection of the composition of sodium alginate and adriamycin hydrochloride
- composition freeze-dried powder injection wherein the sodium alginate concentration is 1, 10, 20, and 40 mg, and adriamycin hydrochloride is 2 mg, and the composition freeze-dried powder injection is reconstituted separately 1 ml of aqueous solution and shake until it is clear and transparent, then add 200 ⁇ l of 5 mg per ml of calcium chloride solution to make it gel, and soak the gel in 1 ml of phosphate buffer solution and stir. 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of doxorubicin hydrochloride.
- Figure 9 shows the release curve of doxorubicin hydrochloride at different concentrations of sodium alginate. It can be seen from the figure that when the concentration of sodium alginate is 10 mg or more, doxorubicin hydrochloride has an obvious slow-release phenomenon, so the combination
- the concentration of sodium alginate in the freeze-dried powder injection is preferably 5 mg/ml to 80 mg/ml.
- adriamycin hydrochloride composition freeze-dried powder injection, wherein the concentration of adriamycin hydrochloride is 1, 2.5, 5, 7.5 and 10 mg (maximum solubility), sodium alginate is 20 mg, and the composition is lyophilized
- the powder injections were re-dissolved in 1 ml of aqueous solution and shaken until clear and transparent, and then 5 mg per ml of calcium chloride solution was added to make it gel, and the gel was immersed in 1 ml of phosphate buffer solution and stirred. 0.25, 0.5, 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of doxorubicin hydrochloride.
- Figure 10 shows the release curve of doxorubicin hydrochloride at different concentrations of doxorubicin hydrochloride. It can be seen from the figure that when the concentration of doxorubicin hydrochloride is higher than 7.5 mg, there is a relatively obvious rapid release, and the subsequent release is also lower than that The concentration should be fast, but the sustained-release effect is still obvious, so the concentration of adriamycin in the composition freeze-dried powder injection is selected to be 0.1-10 mg/ml.
- the preferred mass ratio of sodium alginate and adriamycin hydrochloride obtained through the above experiment is 50-800 to 1-100, and the more preferred mass ratio is 200-400 to 10-75.
- Example 4 Lyophilized powder injection of the composition of sodium alginate (the first component) and oxaliplatin (the second component)
- Step 1 Preparation of freeze-dried powder injection of the composition of sodium alginate and oxaliplatin
- Figure 11 is a scanning electron microscope picture of the composition after the freeze-dried powder injection is reconstituted into a gel. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Step 2 Release curve of oxaliplatin in the lyophilized powder injection of the composition of sodium alginate and oxaliplatin
- Preparation of sodium alginate and oxaliplatin composition freeze-dried powder injection wherein the sodium alginate concentration is 1, 10, 20 and 40 mg, oxaliplatin is 2 mg, and the composition freeze-dried powder injection is re-dissolved separately 1 ml of aqueous solution and shake until it is clear and transparent, then add 200 ⁇ l of 5 mg per ml of calcium chloride solution to make it gel, and soak the gel in 1 ml of phosphate buffer solution and stir. 1,2,4,8 days to determine the content of the drug in the phosphate buffer solution is the release of oxaliplatin.
- Figure 12 shows the oxaliplatin drug release curve at different concentrations of sodium alginate. It can be seen from the figure that when the concentration of sodium alginate is 10 mg or more, oxaliplatin has an obvious slow-release phenomenon, so the combination
- the concentration of sodium alginate in the freeze-dried powder injection is selected from 5 mg/ml to 80 mg/ml.
- Preparation of sodium alginate and oxaliplatin composition freeze-dried powder injection wherein the oxaliplatin concentration is 1, 2.5, 5 and 7.5 mg (maximum solubility), sodium alginate is 20 mg, the composition is freeze-dried powder injection Re-dissolve in 1 ml of the aqueous solution and shake until it is clear and transparent, then add 5 mg per ml of calcium chloride solution to make it gel, and soak the gel in 1 ml of phosphate buffer solution and stir. 0.5, 1, 2, 4, 8 days to determine the content of the drug in the phosphate buffer solution is the release of oxaliplatin.
- Figure 13 shows the oxaliplatin drug release curve at different oxaliplatin concentrations. It can be seen from the figure that when the oxaliplatin concentration is higher than 7.5 mg, there is a relatively obvious acute release and a relatively obvious acute release And the subsequent release is faster than the low concentration, but the sustained release effect is still obvious, so the concentration of oxaliplatin in the composition freeze-dried powder injection is selected to be 0.1-7.5 mg/ml.
- the preferred mass ratio of sodium alginate and oxaliplatin obtained through the above experiment is 50-800 to 1-75, and the more preferred mass ratio is 200-400 to 10-75.
- Example 5 Sodium alginate (first component), doxorubicin hydrochloride (second component) and imiquimod (third component) hydrochloride freeze-dried powder injection
- Step 1 Preparation of sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride freeze-dried powder injection
- Method one (dissolve components one, two and three in the aqueous solution, stir, and then freeze-dry the mixed solution): Weigh 10 to 80 mg of sodium alginate (the first component) and imiquimod (the third Class component) 0.1-10 mg of hydrochloride lyophilized powder and 0.1-10 mg of doxorubicin hydrochloride (the second component) are dissolved in 1 ml of aqueous solution, using a stirring paddle at 50-300 revolutions per minute Stir at a speed until the solution is clear and transparent, and then freeze-dry the solution to obtain a composition freeze-dried powder injection.
- Method two (components one and two are dissolved in the water phase solution, the mixed solution is lyophilized to obtain the lyophilized powder after stirring, and the lyophilized powder is mixed with the lyophilized powder of component three):
- Weigh the sodium alginate (the first component ) 10 ⁇ 80 mg and 0.1 ⁇ 10 mg of doxorubicin hydrochloride (the second component) are dissolved in 1 ml of aqueous solution, stirred with a stirring paddle at a speed of 50 to 300 revolutions per minute until the solution is clear and transparent, and then lyophilized
- the freeze-dried powder is obtained, and 0.1-10 mg of imiquimod (the third component) hydrochloride freeze-dried powder is uniformly mixed by shaking the solid and the solid to obtain the composition freeze-dried powder injection.
- Method three (components two and three are dissolved in the aqueous solution, and a clear solution is obtained after stirring.
- the solution of component one is dropped into the aforementioned mixture at a ratio of 1:20, and then the final mixture is lyophilized to obtain a lyophilized solution.
- Powder Dissolve 0.1-10 mg doxorubicin hydrochloride and 0.1-10 mg imiquimod hydrochloride in 1 ml of aqueous solution, and stir until the solution is reached with a stirring paddle at a speed of 50-300 revolutions per minute.
- the preferred mass ratio of the first component, the second component and the third component in the composition is 50-800 to 1-100 to 1-100, and the more preferred mass ratio is 200 to 400 to 10. ⁇ 75 to 10 ⁇ 75. .
- Figure 14 is a scanning electron microscope picture of the composition after the freeze-dried powder injection is reconstituted into a gel. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Step 2 Determination of rheological properties of sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride freeze-dried powder injection after reconstitution
- Figure 15 shows the rheological properties of different concentrations of sodium alginate, adriamycin and imiquimod composition lyophilized powder after reconstitution after exposure to calcium ions. It can be seen from the figure that when the concentration of sodium alginate is 1 mg/ml, its storage modulus is smaller than the loss modulus, showing fluid behavior. When the concentration of sodium alginate reaches more than 10 mg/ml, its storage modulus The amount is greater than the loss modulus, showing gel behavior, which proves that sodium alginate will form a colloid when it encounters calcium ions above 10 mg/ml.
- Example 6 Sodium alginate (first component), oxaliplatin (second component) and imiquimod hydrochloride (third component) freeze-dried powder injection
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 7.5 mg of oxaliplatin, and dissolve them in 1 ml of aqueous solution. After stirring at a speed of ⁇ 300 revolutions per minute until the solution is clear and transparent, the solution is freeze-dried to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 to 80 mg of sodium alginate and 0.1 to 7.5 mg of oxaliplatin to 1 ml of aqueous solution, stir with a stirring blade at a speed of 50 to 300 revolutions per minute until the solution is clear and transparent, and then freeze-dried. The dry powder is then mixed with 0.1-10 mg of imiquimod hydrochloride lyophilized powder through solid-solid shaking to obtain a composition lyophilized powder injection.
- Method 3 Dissolve 0.1-10 mg of oxaliplatin and 0.1-10 mg of imiquimod hydrochloride in 1 ml of aqueous solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent , And then dissolve 20-80 mg of sodium alginate in 1 ml of aqueous solution, and drop it into the continuously stirred mixed solution at a volume ratio of 1 to 20 to ensure that the mixed solution is clear and transparent without flocculent precipitation. After all the sodium alginate solution has been added, the mixed solution is taken out and freeze-dried to obtain a composition freeze-dried powder injection.
- the mass ratio of the first type component, the second type component and the third type component in the composition is 50-800 to 1 to 75 to 1 to 100, and the more preferred mass ratio is 200 to 400 to 10 to 75 to 10 ⁇ 75. .
- Figure 16 is a scanning electron microscope picture of the freeze-dried powder injection of the composition after gelling. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Example 7 Sodium alginate (first component), pentafluorouracil (second component) and imiquimod hydrochloride (third component) freeze-dried powder injection
- Method 1 Weigh 10 to 80 mg of sodium alginate, 1 to 5 mg of pentafluorouracil and 0.1 to 10 mg of imiquimod hydrochloride, and dissolve in 1 ml of 2 mg per ml of sodium hydroxide solution, and shake it to the solution After being clear and transparent, the solution is freeze-dried to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of sodium alginate and 1 ⁇ 5 mg of pentafluorouracil, dissolve in 1 ml of aqueous solution, shake until the solution is clear and transparent, then freeze-dry to obtain freeze-dried powder and 0.1 ⁇ 10 mg of imiquimod hydrochloride The freeze-dried powder is uniformly mixed by shaking to obtain the composition freeze-dried powder injection.
- Example 8 Sodium alginate (first component), cyclophosphamide (second component) and imiquimod hydrochloride (third component) lyophilized powder injection
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate, 1 ⁇ 5 mg of cyclophosphamide and 0.1 ⁇ 10 mg of imiquimod hydrochloride, and dissolve in 1 ml of aqueous solution. Shake well until the solution is clear and transparent. Freeze-drying to obtain the composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of sodium alginate and 1 ⁇ 5 mg of cyclophosphamide, dissolve in 1 ml of aqueous solution, shake until the solution is clear and transparent, then freeze-dry to obtain freeze-dried powder and 0.1 ⁇ 10 mg of imiquimod hydrochloric acid The freeze-dried salt powder is uniformly mixed by shaking to obtain the composition freeze-dried powder injection.
- Example 9 Sodium alginate (first component), doxorubicin hydrochloride (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth component) Component) Lyophilized powder injection
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, and dissolve in 1 ml of aqueous solution, and shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of anti-PDL1 solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of sodium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of anti-PDL1 solution, mix well and freeze-dried. The dry powder and 0.1-10 mg of imiquimod hydrochloride lyophilized powder are uniformly mixed by shaking to obtain the composition lyophilized powder injection.
- Figure 17 is a scanning electron microscope picture of the freeze-dried powder injection of the composition after gelling. It can be seen from the figure that the composition still has good gel forming ability after freeze-drying and reconstitution, and it can be seen from the electron microscope pictures that there are many micron-level pores after gelling, which is important to the sustained release of drugs.
- Figure 18 shows the activity test of antibody anti-PDL1 after lyophilization. From the experimental results, it can be seen that the peak value of anti-PDL1 antibody binding to cell surface PDL1 antibody flow cytometry after lyophilization is consistent with the peak value of pure anti-PDL1 antibody. It shows that lyophilization does not affect the activity of anti-PDL1 antibody.
- Example 10 Sodium alginate (first component), oxaliplatin (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth component) Component) Lyophilized powder injection
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 7.5 mg of oxaliplatin, and dissolve in 1 ml of aqueous solution, and shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of anti-PDL1 solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of sodium alginate and 0.1 ⁇ 10 mg of oxaliplatin, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of anti-PDL1 solution, mix well and freeze-dried. The dry powder and 0.1-10 mg of imiquimod hydrochloride lyophilized powder are uniformly mixed by shaking to obtain the composition lyophilized powder injection.
- Example 11 Other alginates (first component), doxorubicin hydrochloride (second component), imiquimod hydrochloride (third component), and anti-PDL1 antibody ( The fourth component) freeze-dried powder injection
- Method 1 Weigh 10 ⁇ 80 mg of potassium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride and dissolve in 1 ml of aqueous solution, and shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of anti-PDL1 solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of potassium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of anti-PDL1 solution, mix uniformly and lyophilize. The freeze-dried powder is then mixed with 0.1-10 mg of imiquimod hydrochloride freeze-dried powder and mixed uniformly by solid-solid shaking to obtain a composition freeze-dried powder injection.
- Method 1 Weigh 10 ⁇ 80 mg of ammonium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride and dissolve in 1 ml of aqueous solution, shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of anti-PDL1 solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of ammonium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of anti-PDL1 solution, mix well, and freeze-dried. The dry powder and 0.1-10 mg of imiquimod hydrochloride lyophilized powder are uniformly mixed by shaking to obtain the composition lyophilized powder injection.
- Alginates of different cations can form a good composition with the other three components, and still have the ability to form a gel and release slowly.
- Example 12 Alginate (the first component) and doxorubicin hydrochloride (the second component) and imiquimod hydrochloride (the third component) and IDO inhibitor 4-phenyl Imidazole (fourth component) freeze-dried powder injection
- Method 1 Weigh 10 ⁇ 80 mg of sodium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, and dissolve in 1 ml of aqueous solution, and shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of 4-phenylimidazole solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of sodium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of 4-phenylimidazole solution and mix well.
- the freeze-dried powder is obtained by drying, and the freeze-dried powder is mixed with 0.1-10 mg of imiquimod hydrochloride by solid-solid shaking to obtain a composition freeze-dried powder injection.
- Method 1 Weigh 10 ⁇ 80 mg of potassium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride and dissolve in 1 ml of aqueous solution, and shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of 4-phenylimidazole solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of potassium alginate and 0.1 ⁇ 10 mg of doxorubicin hydrochloride, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of 4-phenylimidazole solution, mix well and freeze dry The obtained freeze-dried powder and 0.1-10 mg of imiquimod hydrochloride freeze-dried powder are uniformly mixed by shaking to obtain a composition freeze-dried powder injection.
- Method 1 Weigh 10 ⁇ 80 mg of ammonium alginate, 0.1 ⁇ 10 mg of imiquimod hydrochloride lyophilized powder and 0.1 ⁇ 10 mg of doxorubicin hydrochloride and dissolve in 1 ml of aqueous solution, shake well until the solution is clear After being transparent, 100 micrograms to 5 mg of 4-phenylimidazole solution are added and mixed uniformly, and the solution is lyophilized to obtain a composition freeze-dried powder injection.
- Method 2 Weigh 10 ⁇ 80 mg of ammonium alginate and 0.1 ⁇ 10 mg of adriamycin hydrochloride, dissolve in 1 ml of aqueous solution and shake until the solution is clear and transparent, then add 100 ⁇ g ⁇ 5 mg of 4-phenylimidazole solution, mix well and freeze dry The obtained freeze-dried powder and 0.1-10 mg of imiquimod hydrochloride freeze-dried powder are uniformly mixed by shaking to obtain a composition freeze-dried powder injection.
- Example 13 Study on the curative effect of the composition of sodium alginate (the first component) and imiquimod hydrochloride (the third component) on a colon cancer model
- Step 1 Sodium alginate (first component) and imiquimod hydrochloride (third component) composition freeze-dried powder injection combined with radiofrequency ablation therapy and immune checkpoint suppression therapy anti-PDL1 antibody efficacy the study.
- mice Mouse colon cancer tumors were planted on the left and right ends of the back of the mice (the left side is regarded as the in situ tumor, the right side is regarded as the distal tumor), and the tumor-bearing mice were divided into four groups, each with 5 mice for treatment experiments.
- Group 1 Radiofrequency ablation treatment of the left orthotopic tumor alone (reference example);
- the second group After radiofrequency ablation of the left tumor in situ, anti-pdl1 antibody was injected into the tail vein (reference example);
- the third group Intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1) on the left side of the tumor, followed by radiofrequency ablation therapy;
- the fourth group Intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1) on the left side of the tumor, followed by radiofrequency ablation therapy plus tail vein injection of anti-PDL1 antibody therapy.
- Step 2 Sodium alginate (first component) and imiquimod hydrochloride (third component) composition freeze-dried powder injection combined with high-energy focused ultrasound knife (HIFU) and immune checkpoint suppression therapy anti- Efficacy study of PDL1 antibody.
- HIFU high-energy focused ultrasound knife
- mice Mouse colon cancer tumors were planted on the left and right ends of the back of the mice (the left side is regarded as the in situ tumor, the right side is regarded as the distal tumor), and the tumor-bearing mice were divided into four groups, each with 5 mice for treatment experiments.
- the first group the left orthotopic tumor is treated with HIFU alone (reference example);
- the second group After HIFU treatment of the left orthotopic tumor, anti-pdl1 antibody was injected into the tail vein (reference example);
- the third group HIFU treatment after intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1) on the left side of the tumor;
- the fourth group Intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1) on the left side of the tumor, followed by HIFU treatment plus tail vein injection of anti-PDL1 antibody treatment.
- Step 3 Sodium alginate (first component) and imiquimod hydrochloride (third component) composition freeze-dried powder injection combined with high-energy focused ultrasound knife (HIFU) and immune checkpoint suppression therapy anti- PDL1 antibody causes immune memory effect research.
- HIFU high-energy focused ultrasound knife
- the colon cancer-bearing mice were divided into six groups, 5 mice in each group.
- the first group the normal saline group
- the second group tail vein anti-PDL1 antibody treatment (reference example);
- the third group HIFU treatment alone (reference example);
- the fourth group tail vein anti-pdl1 antibody treatment after HIFU treatment (reference example);
- the fifth group HIFU treatment after intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1);
- the sixth group intratumoral injection of sodium alginate and imiquimod hydrochloride composition freeze-dried powder injection (Example 1) after HIFU treatment and tail vein anti-PDL1 antibody treatment.
- mice in the fifth and sixth groups were significantly slower than that of the control group, and was significantly inhibited.
- the tumor growth of the sixth group of mice was slower than that of the fifth group, and some of them were no longer able to grow. Grow a tumor.
- Example 14 Study on the curative effect of sodium alginate (first component) and oxaliplatin (second component) composition freeze-dried powder injection on colon cancer model
- the colon cancer-bearing mice were divided into 6 groups, with 5 mice in each group for treatment experiments.
- mice were injected with saline intratumor respectively (reference example);
- the second group Oxaliplatin (1.5 mg per kilogram of body weight) (reference example of single chemotherapeutic agent);
- the third group intratumoral injection of oxaliplatin and sodium alginate composition freeze-dried powder injection (0.375 mg/kg body weight) (Example 4);
- the fourth group intratumoral injection of oxaliplatin and sodium alginate composition freeze-dried powder injection (0.75 mg/kg body weight) (Example 4);
- the fifth group intratumoral injection of oxaliplatin and sodium alginate composition freeze-dried powder injection (1.5 mg/kg body weight) (Example 4);
- the sixth group oxaliplatin (3 mg/kg body weight) was injected into the tail vein (a reference case with a single chemotherapeutic agent).
- mice in the tail vein injection of oxaliplatin group showed a significant weight loss in the first four days, indicating that the intravenous injection has certain toxic and side effects, while the intratumoral injection showed no obvious toxic side effect.
- the side effects of intratumoral administration using the composition of the patent technical scheme are lower than that of intravenous administration.
- Example 15 Sodium alginate (first component), oxaliplatin (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth A study on the efficacy of freeze-dried powder injection on a bilateral tumor (one tumor on the left and right sides) model.
- mice colon cancer tumors were planted on the left and right ends of the back of the mice (the left side is regarded as the in situ tumor, the right side is regarded as the distal tumor), and the tumor-bearing mice are divided into 7 groups, each group has 6 mice for combined immunization experiment.
- mice were injected with saline intratumor respectively (reference example);
- the second group Oxaliplatin, Imiquimod and anti-PDL1 composite solution (reference example);
- the third group sodium alginate and oxaliplatin composition freeze-dried powder injection (Example 4) combined with intravenous injection of anti-PDL1 (reference example);
- the fourth group intratumoral injection of sodium alginate, oxaliplatin and anti-PDL1 composition freeze-dried powder injection (Example 4);
- the fifth group intratumoral injection of sodium alginate, oxaliplatin and imiquimod composition lyophilized powder injection (Example 6);
- the sixth group intratumoral injection of sodium alginate, oxaliplatin and imiquimod anti-PDL1 composition freeze-dried powder injection (Example 10);
- the seventh group sodium alginate, oxaliplatin and imiquimod composition freeze-dried powder injection (Example 6) combined with anti-PDL1 intravenous injection (reference example).
- Example 16 Sodium alginate (first component), doxorubicin hydrochloride (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth The study on the efficacy of freeze-dried powder injection in breast cancer metastasis model
- mice with 4T1 breast cancer tumors in situ on the breast pads were divided into 6 groups, with 6 mice in each group for treatment experiments on metastatic tumor models.
- mice were injected with saline intratumor respectively (reference example);
- the second group doxorubicin and imiquimod hydrochloride and anti-PDL1 antibody (reference example);
- the third group intratumoral injection of sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride composition freeze-dried powder injection (Example 5);
- the fourth group intratumoral injection of sodium alginate, adriamycin hydrochloride and anti-PDL1 antibody composition freeze-dried powder injection (Example 5);
- the fifth group intratumoral injection of sodium alginate, adriamycin, imiquimod and anti-PDL1 antibody composition freeze-dried powder injection (Example 9);
- the sixth group sodium alginate, adriamycin and imiquimod hydrochloride composition freeze-dried powder injection (Example 5) combined with intravenous injection of anti-PDL1 antibody (reference example).
- Example 17 Sodium alginate (first component), doxorubicin hydrochloride (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth (Class-component) Freeze-dried Powder Injection on the Efficacy of Mouse Brain Cancer
- mice The first group: intracranial injection of normal saline in mice (reference example);
- mice were intraperitoneally injected with temotomil (reference example);
- mice were injected intracranially with imiquimod hydrochloride, anti-PDL1 antibody and sodium alginate composition (reference example);
- mice were injected intracranially with a freeze-dried powder injection of a composition of sodium alginate and adriamycin (Example 3);
- mice were injected intracranially with doxorubicin hydrochloride, imiquimod hydrochloride and anti-PDL1 antibody composition (reference example);
- mice were injected intracranially with sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride composition freeze-dried powder injection (Example 5);
- mice were injected intracranially with a combination of sodium alginate, adriamycin hydrochloride and anti-PDL1 antibody (reference example);
- mice are injected intracranially with sodium alginate, adriamycin hydrochloride, imiquimod hydrochloride and anti-PDL1 antibody composition freeze-dried powder injection (Example 9);
- mice were treated with intracranial injection of sodium alginate, adriamycin hydrochloride and imiquimod hydrochloride freeze-dried powder injection (reference example).
- Figure 28 is the mortality curve of mice. It can be seen from the figure that the survival time of mice in the eighth and ninth groups is twice as long as that of the control group, indicating that the treatment effect is better.
- Example 18 Sodium alginate (first component), doxorubicin hydrochloride (second component), imiquimod hydrochloride (third component) and anti-PDL1 antibody (fourth (Class component) freeze-dried powder injection in the mouse model after tumor resection
- mice The subcutaneous breast cancer mice were randomly divided into three groups, and six mice in each group were treated with sodium alginate, adriamycin, imiquimod, and anti-PDL1 antibody composite gel treatment experiment. After the mice were surgically removed most of the subcutaneous tumors (removal of the mouse subcutaneous tumors to preserve their adjacent skin and muscle).
- the first group is not processed (reference example);
- the second group of simple surgery (reference example).
- the treatment effect is judged by observing the metastasis and recurrence of the tumor after surgery, and the conclusion is drawn by small animal bioluminescence imaging. It can be seen from Figure 29 that the tumors of the third group of mice in the key group have a good effect of inhibiting metastasis and recurrence, which proves that our sodium alginate, doxorubicin, imiquimod and anti-PDL1 antibody composite gel The role of.
- Example 19 The pharmaceutical composition of this example can be prepared in two dosage forms.
- the first dosage form is as follows:
- Component 1 according to the ratio of imiquimod R837: surfactant poloxamer 188: (0.1-5). Weigh imiquimod R837 and surfactant poloxamer 188. Preferably 1g R837, add appropriate amount of Poloxamer 188 (0.15g, 0.3g, 0.5g, 1g, 2g, 3g, 4g, 5g), add 10ml water ball mill for 3 hours, after the end, take out 9ml homogenate and transfer to 250ml In the beaker, add 141ml of first-grade water, stir at 500rpm for 1 hour and mix well. Use a syringe to suck the suspension and fill it into 10ml vials of 5ml each, totaling 30 vials. Cover the rubber cover and seal it with the aluminum cover, then sterilize it with moist heat at 121°C for 12 minutes;
- Component 2 Prepare 0.1-5% sodium alginate and 0.1-1% oxaliplatin solution, preferably weigh out sodium alginate ALG (3g, or 1.5g), appropriate amount of oxaliplatin (159mg, 300mg, 450mg) ,90mg), add 300ml first-grade water, stir in a 500ml beaker for 2-6 hours (25°C-40°C, 200-850rpm, seal the bottle with plastic wrap). The obtained solution was filtered through a 0.22 micron filter membrane to sterilize. Fill a 20ml vial with a 60ml syringe, 10ml per bottle, 30 bottles in total. After being pre-cooled in a refrigerator at -80°C for 30 minutes, it was freeze-dried for 30 hours. After freeze-drying, cover the rubber cover and seal the aluminum cover.
- the second dosage form is as follows:
- Component 1 According to the ratio of imiquimod R837:surfactant poloxamer 188 to 1:(0.1-5), weigh R837 and surfactant, and add 0.1-1% oxaliplatin.
- Component 2 Prepare a 0.1-5% solution of sodium alginate. Preferably, weigh 3g or 1.5g of sodium alginate ALG, add 300ml of first-grade water, and stir in a 500ml beaker for 2-6 hours (25°C-40°C, 200-850rpm, seal the bottle with plastic wrap). The obtained solution was filtered through a 0.22 micron filter membrane to sterilize. Fill a 20ml vial with a 60ml syringe, 10ml per bottle, 30 bottles in total. After pre-cooling in the refrigerator at -80°C for 30 minutes, freeze-dry for 30 hours. After freeze-drying, cover the rubber cover and seal the aluminum cover.
- the specific effects of this embodiment for treatment are as follows.
- the first dosage form is used, and the second dosage form has similar therapeutic effects as the first dosage form.
- mice Plant mouse colon cancer tumors on the left and right ends of the back of the mouse (the left side is regarded as the tumor in situ, the right side is regarded as the distal tumor), and the tumor-bearing mice are divided into 5 groups, with 6 mice in each group as a combination Immunity treatment experiment.
- mice were injected with saline intratumor respectively (reference example);
- the second group intratumoral injection of oxaliplatin + poloxamer 188 dispersed imiquimod particles;
- the third group intratumoral injection of oxaliplatin + sodium alginate;
- the fourth group intratumoral injection of Poloxamer 188 dispersed imiquimod particles + sodium alginate;
- the fifth group intratumoral injection of oxaliplatin + poloxamer 188 dispersed imiquimod particles + sodium alginate;
- Poloxamer P188 ball mill is added to R837 ball mill emulsion.
- Poloxamer 188 is a new type of polymer nonionic surfactant. It has many uses including: as emulsifier, stabilizer and solubilizer. Further enhance the water dispersibility and stability of R837 ball mill emulsion.
- solubilizing pharmaceutical excipients used include: poloxamer 188, poloxamer 407, polysorbate 80 (Tween 80), polyethylene glycol-12-hydroxystearate (Solutol HS 15), egg yolk Phospholipids, polyoxyethylene (35) castor oil, vitamin E polyethylene glycol succinate, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 800, or one of sodium hydroxymethyl cellulose Or multiple.
- polysorbate 80 polyethylene glycol-12-hydroxystearate
- Solutol HS 15 polyethylene glycol-12-hydroxystearate
- egg yolk lecithin polyoxyethylene
- polyoxyethylene 35
- castor oil vitamin E succinate polyethylene glycol ester, or sodium hydroxymethyl cellulose have a good solubilizing effect on R837.
- polyethylene glycol 200, polyethylene glycol 400, and polyethylene glycol 800 have general solubilization effects.
- Polysorbate 80 Teween 80
- Polyoxyethylene castor oil as a non-ionic surfactant, although it can increase the water solubility of most insoluble drugs, it will cause the release of histamine and cause a variety of toxic and side effects, such as severe allergic reactions, toxic kidney damage, Neurotoxicity, cardiovascular toxicity, etc.
- Solutol HS 15 has the most toxic and side effects for muscle stimulation and hemolysis experiments, while polyethylene glycol 200 has the least side effects.
- Polyethylene glycol is a stable hydrophilic substance, non-toxic, non-irritating, solubilizing, increasing stability and prolonging effect on many drugs.
- Poloxamer 188 is a series of multi-purpose pharmaceutical excipients. It is non-toxic, non-antigenic, non-sensitizing, non-irritating, non-hemolytic, and chemically stable. Poloxamer 188 is one of the series of excipients with better safety. It has been used clinically as an emulsifier and solubilizer for intravenous administration.
- Poloxamer 188 can help R837 ensure water dispersibility and stability after sterilization.
- Table 1 Water dispersibility of ball milled imiquimod R837 before and after adding surfactant
- Surfactant a Long-term stability after autoclaving 0.15:1 A large number of granular aggregates appear 0.3:1 A large number of granular aggregates appear 0.5:1 A large number of granular aggregates appear 1:1 A large number of granular aggregates appear 2:1 A large number of granular aggregates appear 3:1 Evenly dispersed and no granular aggregates appear 4:1 Evenly dispersed and no granular aggregates appear
- Applicable surfactants include: poloxamer 188, poloxamer 407, polysorbate 80 (Tween 80), polyethylene glycol-12-hydroxystearate (Solutol HS 15), poly Oxyethylene (35) castor oil, vitamin E succinate polyethylene glycol ester, sodium hydroxymethyl cellulose.
- Surfactant b Long-term stability after autoclaving 0.15:1 A large number of granular aggregates appear 0.3:1 A large number of granular aggregates appear 0.5:1 A large number of granular aggregates appear 1:1 Evenly dispersed and no granular aggregates appear 2:1 Evenly dispersed and no granular aggregates appear 3:1 Evenly dispersed and no granular aggregates appear 4:1 Evenly dispersed and no granular aggregates appear 5:1 Evenly dispersed and no granular aggregates appear
- Applicable surfactants include: egg yolk lecithin.
- Surfactant c R837 Long-term stability after autoclaving 0.15:1 Large flocculent aggregates 0.3:1 Large flocculent aggregates 0.5:1 A large number of flocculent aggregates appear 1:1 A large number of flocculent aggregates appear 2:1 Large flocculent aggregates 3:1 A large number of flocculent aggregates appear 4:1 A large number of flocculent aggregates appear 5:1 A large number of flocculent aggregates appear
- Applicable surfactants include: polyethylene glycol 200, polyethylene glycol 400, and polyethylene glycol 800.
- Poloxamer 188 itself is viscous, the concentration is too high, the viscosity is very large, and to avoid introducing impurities.
- Sodium alginate is a relatively special natural biopolymer material. Because it decomposes at high temperatures, it cannot be sterilized by traditional high temperature and humid heat. This patent uses filter sterilization to retain the properties of sodium alginate. In addition, from the perspective of sterilization, sodium alginate and imiquimod R837 cannot be mixed together. Sodium alginate ALG needs to be filtered and sterilized, but R837 particles cannot be filtered (the minimum particle diameter after ball milling is 500nm, and the filter kills Bacteria need a 220nm filter membrane, so they cannot pass); on the other hand, R837 needs moist heat sterilization, and sodium alginate ALG will degrade at high temperature. Therefore, both R837 and ALG cannot be sterilized together.
- Imiquimod R837 needs to be made into ball-milled granular formulations is that if R837 is formulated into hydrochloride, there is a contraindication with OXA, and OXA will react with chloride ions to inactivate; secondly, the hydrochloride of R837 will increase The viscosity of sodium alginate ALG is not convenient to use.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
表面活性剂a:R837 | 高压灭菌后的长期稳定性 |
0.15:1 | 出现大量颗粒状聚集体 |
0.3:1 | 出现大量颗粒状聚集体 |
0.5:1 | 出现大量颗粒状聚集体 |
1:1 | 出现大量颗粒状聚集体 |
2:1 | 出现大量颗粒状聚集体 |
3:1 | 均匀分散且未出现颗粒状聚集体 |
4:1 | 均匀分散且未出现颗粒状聚集体 |
5:1 | 均匀分散且未出现颗粒状聚集体 |
表面活性剂b:R837 | 高压灭菌后的长期稳定性 |
0.15:1 | 出现大量颗粒状聚集体 |
0.3:1 | 出现大量颗粒状聚集体 |
0.5:1 | 出现大量颗粒状聚集体 |
1:1 | 均匀分散且未出现颗粒状聚集体 |
2:1 | 均匀分散且未出现颗粒状聚集体 |
3:1 | 均匀分散且未出现颗粒状聚集体 |
4:1 | 均匀分散且未出现颗粒状聚集体 |
5:1 | 均匀分散且未出现颗粒状聚集体 |
表面活性剂c:R837 | 高压灭菌后的长期稳定性 |
0.15:1 | 出现大量絮状聚集体 |
0.3:1 | 出现大量絮状聚集体 |
0.5:1 | 出现大量絮状聚集体 |
1:1 | 出现大量絮状聚集体 |
2:1 | 出现大量絮状聚集体 |
3:1 | 出现大量絮状聚集体 |
4:1 | 出现大量絮状聚集体 |
5:1 | 出现大量絮状聚集体 |
Claims (10)
- 一种化疗免疫组合药物,其含有能引起免疫原性死亡的化疗药和免疫佐剂,其特征在于:所述化疗免疫组合药物包括第一混合物与第二混合物,所述第一混合物含有免疫佐剂,所述第二混合物含有能引起免疫原性死亡的化疗药;所述能引起免疫原性死亡的化疗药为奥沙利铂,所述免疫佐剂为咪喹莫特R837,还包括有泊洛沙姆188和海藻酸钠ALG;第一混合物为,所述咪喹莫特R837与泊洛沙姆188混合球磨制成得到均匀分散的咪喹莫特乳液,所述咪喹莫特颗粒为0.5-3微米粒径,咪喹莫特乳液经过高温湿热灭菌;第二混合物为,所述海藻酸钠ALG与奥沙利铂与水搅拌混合,经过微米滤膜过滤除菌制成混合物;第一混合物与第二混合物混合构成化疗免疫组合药物。
- 一种化疗免疫组合药物,其含有能引起免疫原性死亡的化疗药和免疫佐剂,其特征在于:所述化疗免疫组合药物包括第一混合物与第二混合物,所述第一混合物含有免疫佐剂,所述第二混合物含有能引起免疫原性死亡的化疗药;所述能引起免疫原性死亡的化疗药为奥沙利铂,所述免疫佐剂为咪喹莫特R837,还包括有泊洛沙姆188和海藻酸钠ALG;第一混合物为,所述咪喹莫特R837与泊洛沙姆188混合球磨制成得到均匀分散的咪喹莫特乳液,所述咪喹莫特颗粒为0.5-3微米粒径,将咪喹莫特乳液与奥沙利铂及水混合搅匀经过高温湿热灭菌;第二混合物为所述海藻酸钠与水混合,然后经过微米滤膜过滤除菌制成混合物;第一混合物与第二混合物混合构成化疗免疫组合药物。
- 根据权利要求1所述的化疗免疫组合药物,其特征在于:所述咪喹莫特R837与泊洛沙姆188的质量配比为1:(0.1-5),所述高温灭菌为105℃~150℃湿热灭菌10-15分钟;所述第二混合物经0.22微米滤膜过滤除菌,并经冻干后制成冻干粉。
- 根据权利要求2所述的化疗免疫组合药物,其特征在于:所述咪喹莫特R837与泊洛沙姆188的质量配比为1:(0.1-5),所述高温灭菌为105℃~150℃湿热灭菌10-15分钟;所述第二混合物经0.22微米滤膜过滤除菌,并经冻干后制成冻干粉。
- 一种化疗免疫组合药物,其含有能引起免疫原性死亡的化疗药和免疫佐剂,其特征在于:所述化疗免疫组合药物包括第一混合物与第二混合物,所述第一混合物含有免疫佐剂,所述第二混合物含有能引起免疫原性死亡的化疗药;第一混合物为,所述免疫佐剂为咪喹莫特,咪喹莫特与表面活性剂混合球磨制成得到均匀分散的咪喹莫特乳液,所述咪喹莫特颗粒为0.5-3微米粒径,咪喹莫特乳液经过高温湿热灭菌,所述表面活性剂为泊洛沙姆407,或聚山梨酯80(吐温80),或聚乙二醇-12-羟基硬脂酸酯(Solutol HS 15),或蛋黄卵磷脂,或聚氧乙烯(35)蓖麻油,或维生素E琥珀酸聚乙二醇酯,或羟甲基纤维素钠中的一种或多种;第二混合物为,海藻酸钠与奥沙利铂与水搅拌混合,经过微米滤膜过滤除菌制成混合物;第一混合物与第二混合物混合构成化疗免疫组合药物。
- 根据权利要求5所述的化疗免疫组合药物,其特征在于:所述海藻酸钠替换为壳聚糖、或纤维蛋白原、或藻酸盐、或透明质酸;所述咪喹莫特R837替换为咪唑喹啉,或吡喃葡糖苷脂质;所述奥沙利铂Oxa替换为蒽环类药物、或环磷酰胺、或硼替佐米、或吉西他滨、或五氟尿嘧啶、或毒素。
- 一种化疗免疫组合药物,其含有能引起免疫原性死亡的化疗药和免疫佐剂,其特征在于:所述化疗免疫组合药物包括第一混合物与第二混合物,所述第一混合物含有免疫佐剂,所述第二混合物含有能引起免疫原性死亡的化疗药;第一混合物为,所述咪喹莫特R837与表面活性剂混合球磨制成得到均匀分散的咪喹莫特乳液,所述咪喹莫特颗粒为0.5-3微米粒径,将咪喹莫特乳液与奥 沙利铂及水混合搅匀经过高温湿热灭菌;所述表面活性剂为泊洛沙姆407,或聚山梨酯80(吐温80),或聚乙二醇-12-羟基硬脂酸酯(Solutol HS 15),或蛋黄卵磷脂,或聚氧乙烯(35)蓖麻油,或维生素E琥珀酸聚乙二醇酯,或羟甲基纤维素钠中的一种或多种;第二混合物为所述海藻酸钠与水混合,然后经过微米滤膜过滤除菌制成混合物;第一混合物与第二混合物混合构成化疗免疫组合药物。
- 根据权利要求7所述的化疗免疫组合药物,其特征在于:所述海藻酸钠能替换为壳聚糖、或纤维蛋白原、或藻酸盐、或透明质酸;所述咪喹莫特R837能替换为咪唑喹啉,或吡喃葡糖苷脂质;所述奥沙利铂Oxa能替换为蒽环类药物、或环磷酰胺、或硼替佐米、或吉西他滨、或五氟尿嘧啶、或毒素。
- 一种化疗免疫组合药物的制备方法,其特征在于包括如下步骤:第一步:按比例1:(0.1-5)称取咪喹莫特R837和表面活性剂泊洛沙姆188,加水球磨2-3小时,结束后取出匀浆,加水,搅拌混匀,105℃~150℃湿热灭菌10-15分钟;第二步:称取海藻酸钠ALG与奥沙利铂,加水,搅拌,将获得的溶液经微米滤膜过滤除菌;预冷后,进行冻干;第三步:将第二步中的冻干粉加入到第一步的混合物溶液中,充分震荡混合均匀。
- 一种治疗结肠癌肿瘤的化疗免疫组合药物,其含有能引起免疫原性死亡的化疗药和免疫佐剂,其特征在于:所述化疗免疫组合药物包括第一混合物与第二混合物,所述第一混合物含有免疫佐剂,所述第二混合物含有能引起免疫原性死亡的化疗药;第一混合物为,所述免疫佐剂为咪喹莫特,咪喹莫特与表面活性剂混合球磨制成得到均匀分散的咪喹莫特乳液,所述咪喹莫特颗粒为0.5-3微米粒径,咪喹莫特乳液经过高温湿热灭菌,所述表面活性剂为泊洛沙姆407,或聚山梨酯 80(吐温80),或聚乙二醇-12-羟基硬脂酸酯(Solutol HS 15),或蛋黄卵磷脂,或聚氧乙烯(35)蓖麻油,或维生素E琥珀酸聚乙二醇酯,或羟甲基纤维素钠中的一种或多种;第二混合物为,海藻酸钠与奥沙利铂与水搅拌混合,经过微米滤膜过滤除菌制成混合物;第一混合物与第二混合物混合构成化疗免疫组合药物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910915738.3 | 2019-09-26 | ||
CN201910915738.3A CN110917345B (zh) | 2019-09-26 | 2019-09-26 | 一种化疗免疫组合药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021056815A1 true WO2021056815A1 (zh) | 2021-04-01 |
Family
ID=69848815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/122492 WO2021056815A1 (zh) | 2019-09-26 | 2020-01-07 | 一种化疗免疫组合药物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN110917345B (zh) |
WO (1) | WO2021056815A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113577266A (zh) * | 2021-08-24 | 2021-11-02 | 南京鼓楼医院 | 一种复合免疫增强剂及其制备方法和应用 |
CN114010592A (zh) * | 2021-11-05 | 2022-02-08 | 苏州百迈生物医药有限公司 | 一种咪喹莫特混悬液制剂及其制备方法和应用 |
CN114053230A (zh) * | 2021-12-09 | 2022-02-18 | 苏州百迈生物医药有限公司 | 一种表柔比星复方制剂及其制备方法和应用 |
CN115192721A (zh) * | 2021-12-09 | 2022-10-18 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物复方制剂及其制备方法和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516073A (zh) * | 2019-09-03 | 2021-03-19 | 苏州百迈生物医药有限公司 | 一种治疗肿瘤的多组分凝胶缓释药物组合物 |
CN116710073A (zh) * | 2020-12-30 | 2023-09-05 | 苏州百迈生物医药有限公司 | 一种自缓释免疫佐剂混悬液及其制备方法和应用 |
WO2022143893A1 (zh) * | 2020-12-30 | 2022-07-07 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物组合物及其制备方法和应用 |
CN114681401A (zh) * | 2020-12-30 | 2022-07-01 | 苏州百迈生物医药有限公司 | 一种自缓释免疫佐剂混悬液及其制备方法和应用 |
CN114681612B (zh) * | 2020-12-30 | 2024-10-25 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物及其制备方法和应用 |
CN114681437A (zh) * | 2020-12-30 | 2022-07-01 | 苏州百迈生物医药有限公司 | 一种米托蒽醌组合物及其制备方法 |
CN114681613B (zh) * | 2020-12-30 | 2024-07-19 | 苏州百迈生物医药有限公司 | 一种原位成胶化疗免疫药物组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079332A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for improving immunotherapy |
CN106456630A (zh) * | 2014-01-10 | 2017-02-22 | 尤罗根制药有限公司 | 用于治疗膀胱原位癌用途的包括咪喹莫特的药物组合物 |
CN106994117A (zh) * | 2016-01-25 | 2017-08-01 | 上海市肿瘤研究所 | 一种治疗胆系肿瘤的药物纳米复合温敏凝胶剂 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
CN1868455A (zh) * | 2006-05-20 | 2006-11-29 | 沈阳药科大学 | 奥沙利铂磷脂复合物静脉给药的纳米混悬注射剂 |
US9393201B2 (en) * | 2009-09-21 | 2016-07-19 | Jw Pharmaceutical Corporation | Oxaliplatin nanoparticles and method for preparing same |
CN103202803B (zh) * | 2012-12-18 | 2015-05-13 | 苏州大学 | 一种咪喹莫特泡囊凝胶剂及其制备方法 |
US9364545B2 (en) * | 2014-06-19 | 2016-06-14 | Taipei Medical University | Thermosensitive injectable hydrogel for drug delivery |
CN109195584A (zh) * | 2015-09-16 | 2019-01-11 | 国家科学研究中心 | 用于治疗恶性肿瘤和/或防止肿瘤复发的胶凝组合物 |
BR112019004042A2 (pt) * | 2016-08-30 | 2019-05-28 | Dana Farber Cancer Inst Inc | composições de liberação de fármaco e usos das mesmas |
AR109629A1 (es) * | 2016-09-08 | 2019-01-09 | Medimmune Llc | Composiciones para la administración local de agonistas de receptores de tipo toll |
-
2019
- 2019-09-26 CN CN201910915738.3A patent/CN110917345B/zh active Active
- 2019-09-26 CN CN202111061706.5A patent/CN113730570A/zh active Pending
-
2020
- 2020-01-07 WO PCT/CN2019/122492 patent/WO2021056815A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106456630A (zh) * | 2014-01-10 | 2017-02-22 | 尤罗根制药有限公司 | 用于治疗膀胱原位癌用途的包括咪喹莫特的药物组合物 |
WO2016079332A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for improving immunotherapy |
CN106994117A (zh) * | 2016-01-25 | 2017-08-01 | 上海市肿瘤研究所 | 一种治疗胆系肿瘤的药物纳米复合温敏凝胶剂 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113577266A (zh) * | 2021-08-24 | 2021-11-02 | 南京鼓楼医院 | 一种复合免疫增强剂及其制备方法和应用 |
CN114010592A (zh) * | 2021-11-05 | 2022-02-08 | 苏州百迈生物医药有限公司 | 一种咪喹莫特混悬液制剂及其制备方法和应用 |
CN114010592B (zh) * | 2021-11-05 | 2024-02-06 | 苏州百迈生物医药有限公司 | 一种可瘤内或瘤周注射的咪喹莫特混悬液制剂及其制备方法和应用 |
CN114053230A (zh) * | 2021-12-09 | 2022-02-18 | 苏州百迈生物医药有限公司 | 一种表柔比星复方制剂及其制备方法和应用 |
CN115192721A (zh) * | 2021-12-09 | 2022-10-18 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物复方制剂及其制备方法和应用 |
CN115192721B (zh) * | 2021-12-09 | 2023-11-07 | 苏州百迈生物医药有限公司 | 一种膀胱灌注药物复方制剂及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110917345B (zh) | 2021-11-09 |
CN110917345A (zh) | 2020-03-27 |
CN113730570A (zh) | 2021-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021056815A1 (zh) | 一种化疗免疫组合药物及其制备方法 | |
CN111375064A (zh) | 一种化疗免疫联合治疗的药物组合物 | |
TW457095B (en) | Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones | |
CN111375062A (zh) | 一种原位成胶化疗免疫联合治疗生物高分子药物组合物 | |
WO2021042778A1 (zh) | 一种治疗肿瘤的温敏型凝胶药物组合物 | |
CN111375065A (zh) | 一种用于肿瘤治疗的生物高分子药物组合物 | |
KR102479259B1 (ko) | 손상된 조직 부위에 주사 가능한 하이드로겔 및 이의 용도 | |
WO2021042777A1 (zh) | 一种治疗肿瘤的多组分凝胶缓释药物组合物 | |
US20230103552A1 (en) | Systems and pharmaceutical compositions for treatment by direct injection of a targeted population of cells | |
US20230405063A1 (en) | Use of probiotic component and pharmaceutical composition containing probiotic component | |
US8481075B2 (en) | Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines | |
KR20240041285A (ko) | 향상된 2단계 미세입자 기반 국소 치료제 전달 시스템 | |
US20230248642A1 (en) | Injectable high-drug-loaded nanocomposite gels and process for making the same | |
CN104288093A (zh) | 纳米药物透皮制剂在肿瘤中的应用 | |
CN108309943A (zh) | 一种基于药物颗粒的复方制剂 | |
CN102526714B (zh) | 治疗肿瘤的药物组合物及其制备方法 | |
CN114344333A (zh) | 动物非致病性细胞相关组分的应用和包含该组分的药物组合物 | |
CN114681613B (zh) | 一种原位成胶化疗免疫药物组合物及其制备方法 | |
CN110269903A (zh) | 一种新型治疗癌症的药物 | |
CN115990136B (zh) | 一种抗肿瘤组合物、纳米制剂、制备方法和用途 | |
Papagiannopoulos et al. | Pharmaceutical applications of carrageenan | |
WO2022068925A1 (zh) | 动物非致病性细胞相关组分的应用和包含该组分的药物组合物 | |
CN114306612A (zh) | 非致病性细胞相关组分的应用以及包含非致病性细胞相关组分的药物组合物 | |
CN115737539A (zh) | 一种大麻二酚热敏纳米水凝胶制剂及其制备方法 | |
CN114681401A (zh) | 一种自缓释免疫佐剂混悬液及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19947137 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19947137 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19947137 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08.11.2022). |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19947137 Country of ref document: EP Kind code of ref document: A1 |